SUBSCRIBE: Print / Digital / eNewsletter
AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford.
Despite heroic efforts by hospitals across the country, the healthcare supply chain has struggled in the fight against COVID-19.
Tagrisso, the targeted therapy made by AstraZeneca, could become the treatment of choice for the majority of lung cancer patients with mutations in a certain gene who are treated after surgery, based on findings presented this past weekend at the American Society of Clinical Oncology annual meeting.
Keytruda, the immunotherapy with more than 20 indications in both blood and solid tumor cancers, doubled rates of progression-free survival for certain patients with metastatic colorectal cancer, according to results presented Sunday at the American Society of Clinical Oncology annual meeting.
Women who get genetic testing for hereditary breast and ovarian cancer are often advised to talk to a genetic counselor before and after they take the test, even if the result is negative for a mutation that would indicate a greater risk.
During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech will be presenting plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.
Ten of thousands of oncologists flock to the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago every year to hear about new drugs. Even preliminary or incremental developments can excite the crowd.
Managed Healthcare Executive recently had a wide-ranging conversation with de Brantes about COVID-19, the healthcare sector and how the precipitous drops in utilization and provider revenue may affect the future of bundled payment and other alternative payment models.
Anna Lee, lead author of the abstract: Changes in Cancer Mortality Rates After the Adoption of the Affordable Care Act, discusses her study with MHE. Lee presented her study May 29 during ASCO 2020's virtual conference.
Sara Douglas, lead investigator of the Abstract: Video Conference Intervention for Distance Caregivers (DCGs) of Patients with Cancer: Improving Psychological Outcomes, discusses her study with MHE's Briana Contreras which will be presented at ASCO 2020.
A fresh look at MURANO data, released this week at the American Society of Clinical Oncology 2020 Annual meeting, shows the poor outcomes that result when patients halt treatment for good, and highlight the need to manage doses carefully to avoid toxicity.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
